Madrigal Pharmaceuticals (MDGL) announced that Mardi Dier has been appointed CFO. Dier was most recently CFO of Acelyrin (SLRN), where she completed the company’s $621M than initial public offering before departing in August 2023. Dier joined Madrigal on February 27, 2024, as an employee in a Senior Advisor role to the Company’s current CFO, Alex Howarth, and will move into the CFO role on March 11, 2024. Mr. Howarth is expected to continue with the Company as a Senior Advisor until March 31, 2024, to ensure a smooth transition of responsibilities to Ms. Dier.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDGL:
- Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
- Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
- Madrigal opportunity in MASH remains after Boehringer data, says UBS
- Madrigal Pharmaceuticals downgraded to Sell at B. Riley after competitor data
- Madrigal Pharmaceuticals downgraded to Sell from Neutral at B. Riley
